{
  "slug": "inositol",
  "name": "Inositol (Myo-Inositol)",
  "alternate_names": [
    "myo-Inositol",
    "D-chiro-Inositol",
    "MI",
    "DCI",
    "MI:DCI 40:1",
    "cyclohexanehexol",
    "Vitamin B8 (former designation)"
  ],
  "mechanism": [
    "Second messenger in the insulin signaling pathway — inositol phosphoglycans (PI/PIP2/PIP3) are core components of the PI3K/Akt cascade",
    "Modulation of ovarian FSH signaling — influences aromatase activity and androgen-to-estrogen conversion",
    "Promotes GLUT4 translocation, supporting peripheral glucose uptake in research models",
    "Phosphatidylinositol membrane phospholipid synthesis (PI/PIP2/PIP3 signaling system)",
    "Osmoregulatory function (renal and brain tissue osmotic balance)"
  ],
  "target": [
    "PI3K/Akt pathway",
    "GLUT4 transporter",
    "FSH receptor",
    "Aromatase",
    "Protein kinase C (PKC)",
    "Inositol phosphoglycan (IPG) mediators"
  ],
  "use_case": [
    "metabolic markers (insulin sensitivity / glucose homeostasis surrogates in research)",
    "reproductive-endocrine markers (PCOS hormonal/metabolic indices in trials)",
    "ovarian-function markers (oocyte quality / ovarian reserve in IVF research)",
    "gestational-diabetes-prevention research (pregnancy populations)",
    "anxiety/panic research (high-dose 12-18 g/day psychiatric trials)",
    "neural-tube-defect-prevention research (pilot/observational)"
  ],
  "body_system": [
    "ENDO",
    "REPRO",
    "METABOLISM",
    "CNS",
    "CELL"
  ],
  "evidence_tier": "A",
  "evidence_anchor_pmid_count": 4,
  "dosage_range": "myo-Inositol 2-4 g/day most commonly studied (metabolic/PCOS research); MI:DCI 40:1 combination is the clinically validated plasma ratio (Nordio 2019); anxiety/panic research used 12-18 g/day (far above typical supplement doses). Educational reference only — not a recommendation.",
  "safety_notes": "Generally well tolerated; Greff 2023 meta-analysis characterized inositol as \"effective and safe.\" Most common adverse effects are mild gastrointestinal (nausea, diarrhea, bloating), more frequent at high doses (12-18 g/day). The MI:DCI ratio should be 40:1 — high-dose D-chiro-inositol used alone may impair ovarian function (Nordio 2019). No formal upper limit established; highest common research dose is myo-inositol 4 g/day. Pregnancy use for GDM-prevention research occurred under medical supervision — a medical decision, not a self-care recommendation. No adequate data outside studied populations.",
  "regulatory": {
    "fda": "GRAS; lawful dietary supplement ingredient; mature market. FDA structure/function claims (e.g., metabolic/cellular-signaling support) permitted with mandatory DSHEA disclaimer — disease implications must be avoided. No FDA-authorized health claim.",
    "efsa": "Listed permissible food-supplement ingredient under Directive 2002/46/EC. NO EFSA-authorized health claim (a claim application was submitted in the EU but did not obtain EFSA authorization).",
    "anvisa": "Usable under the ANVISA dietary-supplement framework (functional-claim framework). China NMPA: lawful food additive (GB 2760) and nutritional fortifier (GB 14880); permitted in health foods."
  },
  "authorized_claims": [],
  "ingredient_hub_url": "https://asxan.ai/ingredients/inositol/",
  "related_goal_slugs": [
    "reproductive-health",
    "menopause-support"
  ],
  "related_lifestyle_slugs": [
    "menopause"
  ],
  "last_evidence_review": "2026-06-13",
  "schema_version": "nc-public-v0.2",
  "api_version": "nc-public-v0.3",
  "_meta": {
    "last_evidence_review": "2026-06-13",
    "ip_axes_disclosed": {
      "public_axes": [
        "mechanism",
        "target",
        "use_case",
        "body_system",
        "evidence_tier",
        "dosage_range",
        "safety_notes",
        "regulatory",
        "authorized_claims"
      ],
      "ip_axes_not_exposed": [
        "proprietary_formula_ratios",
        "clinical_protocol_internals",
        "rnd_pipeline_compounds",
        "supplier_specific_grade_specifications",
        "unpublished_endpoint_data"
      ],
      "rationale": "asxan.ai surfaces the educational, evidence-tier-disclosed slice. Formula composition, clinical-protocol internals, and RnD pipeline data are intentionally outside this public surface."
    }
  }
}